What is NeuCyte?
NeuCyte, Inc. is an early-stage biotechnology firm focused on pioneering treatments for neurological disorders. Leveraging a proprietary human induced pluripotent stem cell (iPSC) technology platform, the company excels in producing high-quality iPSC-derived neural cells. These cells are instrumental in drug discovery efforts targeting debilitating conditions such as Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), epilepsy, and autism. NeuCyte provides a comprehensive suite of services, including custom cell generation, assay development, and functional phenotypic assessments, all designed to accelerate and optimize central nervous system (CNS) drug discovery for biopharmaceutical companies and research institutions.
How much funding has NeuCyte raised?
NeuCyte has raised a total of $7M across 2 funding rounds:
Series A
$6.7M
Debt
$350K
Series A (2018): $6.7M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Key Investors in NeuCyte
PPP
Public-Private Partnership
What's next for NeuCyte?
The substantial enterprise-level backing NeuCyte has received signals a pivotal growth phase. This capital infusion is expected to fuel the advancement of its iPSC-based technology and the expansion of its drug discovery services. The company is strategically positioned to deepen its impact on neurological disease research, potentially leading to the development of novel therapeutic interventions. Future endeavors will likely involve scaling operations, forging strategic partnerships within the biopharmaceutical ecosystem, and further validating its platform's efficacy in preclinical and clinical settings.
See full NeuCyte company page
